Policy & Regulation
Deciphera Pharmaceuticals Names Susan L. Kelley, M.D., to its Board of Directors
11 July 2019 - - US-based clinical-stage biopharmaceutical company Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) has appointed Susan L. Kelley, M.D. to its board of directors, the company said.
Kelley will serve as an independent director and member of the compensation committee.
Dr. Kelley brings to Deciphera over 25 years of experience across all stages of oncology drug research and development. Most recently she served as chief medical officer of the Multiple Myeloma Research Consortium where she led the strategic design and management of clinical trials conducted by leading myeloma clinical research centers in North America.
Prior to the MMRC, she held positions of increasing responsibility at Bayer Healthcare Pharmaceuticals and Bayer-Schering Pharma, including vice president, Global Clinical Development and Therapeutic Area Head Oncology, where she led the team responsible for the development and worldwide regulatory approval of Nexavar (sorafenib).
Prior to joining Bayer, Kelley worked at Bristol-Myers Squibb in Oncology and Immunology drug development, ultimately serving as executive director, Oncology Clinical Research, at the Bristol-Myers Squibb Pharmaceutical Research Institute.
She currently serves as a member of the board of directors at multiple publicly traded companies including VBL Therapeutics, Daré Bioscience, Inc., and ArQule, Inc. Dr. Kelley received her M.D. from Duke University School of Medicine.
She was a Fellow in Medical Oncology and Clinical Fellow in Medicine at Dana-Farber Cancer Institute, Harvard Medical School, and a Fellow in Medical Oncology and Pharmacology at Yale University School of Medicine, where she also served as a Clinical Assistant Professor of Medicine.
Deciphera Pharmaceuticals (NASDAQ: DCPH) is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies.
Its small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers.
Login
Username:

Password: